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10 patients with relapsed/refractory HD (n=7), diffuse Large 
B Cell (n=2) and follicular B-cell NHL (n=1) were treated. 
Median age was 41 years (range 20-61) and median number of 
previous lines of therapy was 3 (range 2-4). Conditioning 
chemotherapy consisted of high-dose melphalan 140 mg/sqm 
for all patients except one heavily pre-treated. 
Hypofractionated TLI was delivered as a12 Gy radiotherapy 
course in 3 consecutive daily fractions followed after 2 days 
rest by HDT and hHSCT. A conventional 3D-CRT-TLI plan was 
compared with all HT-TLI plan for all patients. Daily IGRT was 
performed to validate the patients setup margins reliability 
due to the large extension of the target (from the nodal 
chains of the neck to the inguinal ones included the spleen). 
Outcomes measures were treatment related mortality (TRM), 
progression free survival (PFS) and overall survival (OS). 
Results: All patients had chemosensitive disease at salvage 
chemotherapy, with complete remission (CR) obtained in 6 
patients (HD=5, NHL= 1), and partial remission (PR) in 4. 
Conditioning regimen was very well tolerated. All patients 
showed complete engraftment and median time to neutrophil 
and platelet recovery was of 15 (range 9-21) and 17 days 
(range 9-21), respectively. Three patients developed grade 
3/4 mucositis, grade 2 vomiting and 5 reported fever of 
undetermined origin. There was no TRM within the first 100 
days. After a median follow-up of 36 months (range 31 – 44) 
the 3-year PFS and OS were 50% and 90% respectively. In HL 
patients the 3-year PFS was 71% and OS was 100%. HT-TLI in 
comparison with conformal 3D-CRT-TLI reduced the mean 
and the higher (V80%) doses to the organs at risk from 5% to 
76% and from 47% to 100% respectively. The target volume 
was irradiated with higher conformity and homogeneity with 
HT. Measured setup corrections and replanned dose on daily 
MVCT scans showed robustness of the patient immobilization 
technique. 
Conclusions: Although from a limited number of patients, 
this original analysis showed the clinical feasibility of 
hypofractionate HT-TLI with HDT and ASCT. Preliminary 
outcomes in high risk HL shown remarkable efficacy to be 
considered as safe and effective eligible treatment. 
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Purpose/Objective: To analyze toxicities, dosimetry 
parameters, and oncology outcomes in a series of patients 
with retroperitoneal sarcoma treated with Intensity 
Modulated Radiotherapy (IMRT).  
Materials and Methods: Retrospective analysis of 35 
consecutive patients with histologically proven 
retroperitoneal sarcoma treated with IMRT from 2006 to 2013 
in our institution. IMRT was delivered in a step-and-shoot 
technique with daily IGRT. Toxicity was described following 
the CTCAE v4 classification. As several patients had some 
symptoms before IMRT, we made a matched-pair comparison 
(paired-sample sign test) between treatment related 
acute/chronic toxicities and baseline symptoms. Relapse-free 
and survival intervals were estimated by using Kaplan-Meier 
method. 
Results: Median follow up was 28 months. Of the 35 patients 
there were 18 women and 17 men. Median age 57 was years 
(22-74). 19 and 16 patients were treated after extended 
resection, and preoperatively, respectively. 24 patients 
presented a primary tumor, and 11 were treated for a first 
local recurrence. 26 patients presented a liposarcoma (11 G1, 
4 G2 and 11 G3). Median tumor size was 17.5 cm (5-30). 
Median radiotherapy dose was 50.40 Gy with 1.8 Gy fractions. 
Median dosimetry values were: PTV volume 1033cc, 
contralateral kidney 3.68 Gy, and peritoneal Cavity 22.34 Gy. 
The most frequent acute toxicity was gastrointestinal (GI) 
(26/35, mainly G1; 18 patients), followed by lymphopenia 
(22/35, all without clinical significance). Most frequent (no 
clinically relevant) ≥ G2 toxicities were: lymphopenia (n=19), 
GI (n=8) and albumine decrease (n=3). Late ≥ G2 toxicities 
were: GI (n=6), fatigue (n=3), lymphopenia (n=3), kidney 
injury (n=2) and anemia (n=2). In comparison with baseline, 
there were found significant differences in the following 
acute (fatigue [p=0.04], GI [p<0.001], and lymphopenia 
[p<0.001]) and late (≤G2 kidney injury [p=0.008]) toxicities. 
Recurrences were observed in 11 patients: local (n=10), 
sarcomatosis (n=3) and distant (n=5; 2 Lung, 1 Liver, 1 bone, 
1 Node). A salvage treatment was delivered in all patients. 
Median time to local failure was 8 months (0-35). At 2-year, 
disease free survival, locoregional free–survival, and overall-
survival rates were 77%, 82%, and 83%, respectively. 
Conclusions: IMRT for retroperitoneal sarcomas is well 
tolerated with no acute clinically relevant severe toxicity. 
Mild late Kidney injury was observed in 23% pts. Outcomes 
are consistent with those observed in recent studies. The 
ongoing trial EORTC 62092-22092 is awaited to establish the 
true role of high precision preoperative radiotherapy in 
retroperitoneal sarcoma. 
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Purpose/Objective: Craniospinal irradiation (CSI) is indicated 
for various diseases of the central nervous system, such as 
germinoma, medulloblastoma and ependymoma, in curative 
settings, or as palliative treatment in patients with good 
performance status suffering from meningeosis 
carcinomatosa. Due to the irradiation of a very large volume 
and its close proximity to the vertebrae, a major side effect 
of CSI is bone marrow suppression. We performed a 
treatment plan comparison of 3D and IMRT as TomoTherapy 
to evaluate the different techniques regarding bone marrow 
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sparing.  
Materials and Methods: We retrospectively analyzed 10 adult 
patients undergoing CSI at our institution. All patients were 
treated with TomoTherapy (Accuray, Palo Alto, USA). For 
comparison, all treatment plans were standardized for 
delivery of 36 Gy. The plans were not specifically optimized 
for bone marrow sparing. Additionally, for each patient we 
calculated a 3D conventional plan (3D-CRT) using two 
opposed cranial fields with two attached spinal fields. Based 
on the published data by J.A.Hayman et al. active bone 
marrow compartments were delineated. We compared the 
treatment plans (TomoTherapy vs. 3D-CRT) with respect to 
the mean values for the whole active bone marrow and 
calculated 'weighted bone marrow exposure' (WBME). We 
defined WBME as the sum of all products of mean 
proliferating bone marrow according to anatomical site and 
the mean dose to the anatomical site based on the results of 
J.A. Hayman et al.: WBME =∑(mean marrow according to 
anatomical site * mean dose to anatomical site). 
Results: Mean of mean doses accross all patients for the 
particular bone marrow compartments are shown in the table 
1. Mean values for the whole active bone marrow were higher 
in TomoTherapy plans for each patient with the mean 
difference of ca. 19% (Range 13-37%). Also when taken into 
account the WBME, TomoTherapy treatment plans delivered 
higher dose to active bone marrow in each patient, however 
the mean difference was lower – ca. 13% (Range 2-25%). 
Table 1: Mean of mean doses according to the particular 
bone marrow compartment 
 
 
Conclusions: If not optimized to spare active bone marrow 
CSI, 3D-CRT is superior to TomoTherapy with respect to 
active bone marrow sparing. Except for the sternum, 3D-CRT 
results in almost equivalent or better dose sparing of all bone 
marrow compartments. To evaluate the bone marrow sparing 
the use of WBME seems prudent as the quantitative active 
bone marrow distribution doesn’t follow the absolute bone 
marrow distribution. Whether active bone marrow sparing 
optimized TomoTherapy plans yield superior results is a 
matter of ongoing research. 
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Purpose/Objective: Proper staging of intracranial disease 
with an accurate assessment of the exact number of brain 
lesions is of utmost importance in the decision-making 
process for the appropriate treatment of patients with brain 
metastases. The diagnostic efficacy in the detection of 
additional brain metastases of a three-dimensional, T1-
Weighted Gradient-Echo Imaging with a double contrast was 
evaluated 
Materials and Methods: Before undergoing radiosurgical 
treatment, patients underwent a brain magnetic resonance 
imaging (MRI) scan to be used during the treatment planning 
in order to contour the targets and to locate the brain lesions 
as they relate to the stereotactic frame.  
All the patients underwent a post-contrast study with T1-
weighted, 3D Magnetization-Prepared Rapid Acquisition 
Gradient Echo (MP RAGE) sequence. We used a double dose 
of gadobenate dimeglumine and slice thickness of 1 mm.  
Results: Starting from October 2012 to August 2014, we 
treated with Gamma Knife radiosurgery (GKRS) 113 patients 
with brain metastases. On the diagnostic MRI, all the patients 
had a number of lesions ≤4. Median time interval between 
diagnostic MRI scan and the day of GKRS was 13 days (range 
5-22)  
A total of 87 additional lesions were detected on MR imaging 
performed in the same day of the GKRS in forty patients out 
of 113 (35.4%). A median number of 2 additional lesions were 
detected (range 1-11). Among these 40 patients only 18 
patients had a number of lesions ≤4 on the day of treatment. 
Patients with a total number of lesions ≤10 were treated with 
GKRS. Two patients with a total number of lesions > 10 were 
treated with whole brain radiotherapy (WBRT).  
Conclusions: A double-contrast study with T1-weighted, 
volumetric MPRAGE sequence, using acquisition of contiguous 
1-mm slices may offer a definitely better staging for patients 
with brain metastases. In our opinion, a diagnostic high 
resolution MRI should be recommended in all the patients 
with newly diagnosed brain metastases because the detection 
of the real number of lesions is crucial for an adequate 
treatment and it also may lead to choose different 
therapeutic strategies other than radiosurgery.  
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Purpose/Objective: CNAO (Centro Nazionale di Adroterapia 
Oncologica) started clinical activity with proton beam in 
